HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma (Q2906475): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Import item from Portugal) |
(Changed an Item) |
||||||||||||||
| Property / thematic objective | |||||||||||||||
| Property / thematic objective: Research and innovation / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / date of last update | |||||||||||||||
23 May 2023
| |||||||||||||||
| Property / date of last update: 23 May 2023 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Revision as of 20:09, 23 May 2023
Project Q2906475 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma |
Project Q2906475 in Portugal |
Statements
203,999.02 Euro
0 references
239,998.85 Euro
0 references
85.0 percent
0 references
1 January 2018
0 references
30 June 2021
0 references
INSTITUTO PORTUGUÊS DE ONCOLOGIA DO PORTO FRANCISCO GENTIL - E.P.E.
0 references
Q2997125 (Deleted Item)
0 references
23 May 2023
0 references
Identifiers
POCI-01-0145-FEDER-029030
0 references